Angiotensin-converting enzyme

From Wikipedia, the free encyclopedia
Not to be confused with Angiotensin-converting enzyme 2 (ACE2).
Angiotensin-converting enzyme
Identifiers
EC no.3.4.15.1
CAS no.9015-82-1
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
ACE
PDB 1o86 EBI.jpg
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesACE, angiotensin I converting enzyme, ACE1, CD143, DCP, DCP1, ICH, MVCD3, Angiotensin-converting enzyme
External IDsOMIM: 106180 MGI: 87874 HomoloGene: 37351 GeneCards: ACE
Orthologs
SpeciesHumanMouse
Entrez

1636

11421

Ensembl

ENSG00000159640

ENSMUSG00000020681

UniProt

P12821

P09470

RefSeq (mRNA)

NM_009598
NM_207624
NM_001281819

RefSeq (protein)

NP_001268748
NP_033728
NP_997507

Location (UCSC)Chr 17: 63.48 – 63.5 MbChr 11: 105.97 – 105.99 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Angiotensin-converting enzyme (EC 3.4.15.1), or ACE, is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin II. Therefore, ACE indirectly increases blood pressure by causing blood vessels to constrict. ACE inhibitors are widely used as pharmaceutical drugs for treatment of cardiovascular diseases.[5]

The enzyme was discovered by Leonard T. Skeggs Jr. in 1956.[6] The first crystal structure of human testis ACE was solved in the year 2002 by R. Natesh in the lab of K. Ravi Acharya and the work was published in the journal Nature in January 2003.[7] It is located mainly in the capillaries of the lungs but can also be found in endothelial and kidney epithelial cells.[8]

Other less known functions of ACE are degradation of bradykinin,[9] substance P[10] and amyloid beta-protein.[11]

Nomenclature[]

ACE is also known by the following names:

  • dipeptidyl carboxypeptidase I
  • peptidase P
  • dipeptide hydrolase
  • peptidyl dipeptidase
  • angiotensin converting enzyme
  • kininase II
  • angiotensin I-converting enzyme
  • carboxycathepsin
  • dipeptidyl carboxypeptidase
  • "hypertensin converting enzyme" peptidyl dipeptidase I
  • peptidyl-dipeptide hydrolase
  • peptidyldipeptide hydrolase
  • endothelial cell peptidyl dipeptidase
  • peptidyl dipeptidase-4
  • PDH
  • peptidyl dipeptide hydrolase
  • DCP
  • CD143

Function[]

ACE hydrolyzes peptides by the removal of a dipeptide from the C-terminus. Likewise it converts the inactive decapeptide angiotensin I to the octapeptide angiotensin II by removing the dipeptide His-Leu.[12]

proposed ACE catalytic mechanism

ACE is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body.

Schematic diagram of the renin–angiotensin–aldosterone system

Angiotensin II is a potent vasoconstrictor in a substrate concentration-dependent manner.[13] Angiotensin II binds to the type 1 angiotensin II receptor (AT1), which sets off a number of actions that result in vasoconstriction and therefore increased blood pressure.

Anatomical diagram of the renin–angiotensin system, showing the role of ACE at the lungs.[14]

ACE is also part of the kinin-kallikrein system where it degrades bradykinin, a potent vasodilator, and other vasoactive peptides.[15]

Kininase II is the same as angiotensin-converting enzyme. Thus, the same enzyme (ACE) that generates a vasoconstrictor (ANG II) also disposes of vasodilators (bradykinin).[14]

Mechanism[]

ACE is a zinc metalloproteinase.[16] The zinc ion is essential to its activity, since it directly participates in the catalysis of the peptide hydrolysis. Therefore, ACE can be inhibited by metal-chelating agents.[17]

ACE in complex with inhibitor lisinopril, zinc cation shown in grey, chloride anions in yellow. Based on PyMOL rendering of PDB 1o86 The picture shows that lisinopril is a competitive inhibitor, since it has a similar structure to angiotensin I and binds to the active site of ACE. The structure of ACE and lisinopril complex was solved in the year 2002 and published in 2003.[7]

The E384 residue was found to have a dual function. First it acts as a general base to activate water as a nucleophile. Then it acts as a general acid to cleave the C-N bond.[18]

The function of the chloride ion is very complex and is highly debated. The anion activation by chloride is a characteristic feature of ACE.[19] It was experimentally determined that the activation of hydrolysis by chloride is highly dependent on the substrate. While it increases hydrolysis rates for e.g. Hip-His-Leu it inhibits hydrolysis of other substrates like Hip-Ala-Pro.[18] Under physiological conditions the enzyme reaches about 60% of its maximal activity toward angiotensin I while it reaches its full activity toward bradykinin. It is therefore assumed that the function of the anion activation in ACE provides high substrate specificity.[19] Other theories say that the chloride might simply stabilize the overall structure of the enzyme.[18]

Genetics[]

The ACE gene, ACE, encodes two isozymes. The somatic isozyme is expressed in many tissues, mainly in the lung, including vascular endothelial cells, epithelial kidney cells, and testicular Leydig cells, whereas the germinal is expressed only in sperm. Brain tissue has ACE enzyme, which takes part in local RAS and converts Aβ42 (which aggregates into plaques) to Aβ40 (which is thought to be less toxic) forms of beta amyloid. The latter is predominantly a function of N domain portion on the ACE enzyme. ACE inhibitors that cross the blood–brain barrier and have preferentially selected N-terminal activity may therefore cause accumulation of Aβ42 and progression of dementia.[citation needed]

Disease relevance[]

ACE inhibitors are widely used as pharmaceutical drugs in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus.

ACE inhibitors inhibit ACE competitively.[20] That results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, which leads to systematic dilation of the arteries and veins and a decrease in arterial blood pressure. In addition, inhibiting angiotensin II formation diminishes angiotensin II-mediated aldosterone secretion from the adrenal cortex, leading to a decrease in water and sodium reabsorption and a reduction in extracellular volume.[21]

ACE's effect on Alzheimer's disease is still highly debated. Alzheimer patients usually show higher ACE levels in their brain. Some studies suggest that ACE inhibitors that are able to pass the blood-brain-barrier (BBB) could enhance the activity of major amyloid-beta peptide degrading enzymes like neprilysin in the brain resulting in a slower development of Alzheimer's disease.[22] More recent research suggests that ACE inhibitors can reduce risk of Alzheimer's disease in the absence of apolipoprotein E4 alleles (ApoE4), but will have no effect in ApoE4- carriers.[23] Another more recent hypothesis is that higher levels of ACE can prevent Alzheimer's. It is assumed that ACE can degrade beta-amyloid in brain blood vessels and therefore help prevent the progression of the disease.[24]

A negative correlation between the ACE1 D-allele frequency and the prevalence and mortality of COVID-19 has been established.[25]

Pathology[]

  • Elevated levels of ACE are also found in sarcoidosis, and are used in diagnosing and monitoring this disease. Elevated levels of ACE are also found in leprosy, hyperthyroidism, acute hepatitis, primary biliary cirrhosis, diabetes mellitus, multiple myeloma, osteoarthritis, amyloidosis, Gaucher disease, pneumoconiosis, histoplasmosis and miliary tuberculosis. It is also noted in some patients with extensive plaque psoriasis.
  • Serum levels are decreased in renal disease, obstructive pulmonary disease, and hypothyroidism.

Influence on athletic performance[]

The angiotensin converting enzyme gene has more than 160 polymorphisms described as of 2018.[26]

Studies have shown that different genotypes of angiotensin converting enzyme can lead to varying influence on athletic performance.[27][28]

The rs1799752 I/D polymorphism consists of either an insertion (I) or absence (D) of a 287 base pair alanine sequence in intron 16 of the gene.[26] The DD genotype is associated with higher plasma levels of the ACE protein, the DI genotype with intermediate levels, and II with lower levels.[26] During physical exercise, due to higher levels of the ACE for D-allele carriers, hence higher capacity to produce angiotensin II, the blood pressure will increase sooner than for I-allele carriers. This results in a lower maximal heart rate and lower maximum oxygen uptake (VO2max). Therefore, D-allele carriers have a 10% increased risk of cardiovascular diseases. Furthermore, the D-allele is associated with a greater increase in left ventricular growth in response to training compared to the I-allele.[29] On the other hand, I-allele carriers usually show an increased maximal heart rate due to lower ACE levels, higher maximum oxygen uptake and therefore show an enhanced endurance performance.[29] The I allele is found with increased frequency in elite distance runners, rowers and cyclists. Short distance swimmers show an increased frequency of the D-allele, since their discipline relies more on strength than endurance.[30][31]

See also[]

References[]

  1. ^ Jump up to: a b c GRCh38: Ensembl release 89: ENSG00000159640 - Ensembl, May 2017
  2. ^ Jump up to: a b c GRCm38: Ensembl release 89: ENSMUSG00000020681 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Kaplan's Essentials of Cardiac Anesthesia. Elsevier. 2018. doi:10.1016/c2012-0-06151-0. ISBN 978-0-323-49798-5. Mechanisms of Action:ACE inhibitors act by inhibiting one of several proteases responsible for cleaving the decapeptide Ang I to form the octapeptide Ang II. Because ACE is also the enzyme that degrades bradykinin, ACE inhibitors increase circulating and tissue levels of bradykinin (Fig. 8.4).
  6. ^ Skeggs LT, Kahn JR, Shumway NP (Mar 1956). "The preparation and function of the hypertensin-converting enzyme". The Journal of Experimental Medicine. 103 (3): 295–9. doi:10.1084/jem.103.3.295. PMC 2136590. PMID 13295487.
  7. ^ Jump up to: a b Natesh R, Schwager SL, Sturrock ED, Acharya KR (2003). "Crystal structure of the human angiotensin-converting enzyme-lisinopril complex". Nature. 421 (6922): 551–4. Bibcode:2003Natur.421..551N. doi:10.1038/nature01370. PMID 12540854. S2CID 4137382.
  8. ^ Kierszenbaum, Abraham L. (2007). Histology and cell biology: an introduction to pathology. Mosby Elsevier. ISBN 978-0-323-04527-8.
  9. ^ Fillardi PP (2015). ACEi and ARBS in Hypertension and Heart Failure. Volume 5. Switzerland: Springer International Publishing. pp. 10–13. ISBN 978-3-319-09787-9. |volume= has extra text (help)
  10. ^ Dicpinigaitis PV (January 2006). "Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines". Chest. 129 (1 Suppl): 169S–173S. doi:10.1378/chest.129.1_suppl.169S. PMID 16428706.
  11. ^ Hemming ML, Selkoe DJ (November 2005). "Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor". The Journal of Biological Chemistry. 280 (45): 37644–50. doi:10.1074/jbc.M508460200. PMC 2409196. PMID 16154999.
  12. ^ Coates D (Jun 2003). "The angiotensin converting enzyme (ACE)". The International Journal of Biochemistry & Cell Biology. Renin–Angiotensin Systems: State of the Art. 35 (6): 769–73. doi:10.1016/S1357-2725(02)00309-6. PMID 12676162.
  13. ^ Zhang R, Xu X, Chen T, Li L, Rao P (May 2000). "An assay for angiotensin-converting enzyme using capillary zone electrophoresis". Analytical Biochemistry. 280 (2): 286–90. doi:10.1006/abio.2000.4535. PMID 10790312.
  14. ^ Jump up to: a b Boulpaep EL, Boron WF (2005). "Integration of Salt and Water Balance". Medical Physiology: a Cellular and Molecular Approach. Philadelphia, Pa.: Elsevier Saunders. pp. 866–867. ISBN 978-1-4160-2328-9.
  15. ^ Imig JD (Mar 2004). "ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement". Hypertension. 43 (3): 533–5. doi:10.1161/01.HYP.0000118054.86193.ce. PMID 14757781.
  16. ^ Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, Llorens-Cortes C, Hazra S, Murray AG, Vederas JC, Oudit GY (May 2016). "Angiotensin Converting Enzyme 2 Metabolizes and Partially Inactivates Pyrapelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System". Hypertension. 68 (2): 365–77. doi:10.1161/HYPERTENSIONAHA.115.06892. PMID 27217402. S2CID 829514.
  17. ^ Bünning P, Riordan JF (Jul 1985). "The functional role of zinc in angiotensin converting enzyme: implications for the enzyme mechanism". Journal of Inorganic Biochemistry. 24 (3): 183–98. doi:10.1016/0162-0134(85)85002-9. PMID 2995578.
  18. ^ Jump up to: a b c Zhang C, Wu S, Xu D (Jun 2013). "Catalytic mechanism of angiotensin-converting enzyme and effects of the chloride ion". The Journal of Physical Chemistry B. 117 (22): 6635–45. doi:10.1021/jp400974n. PMID 23672666.
  19. ^ Jump up to: a b Bünning P (1983). "The catalytic mechanism of angiotensin converting enzyme". Clinical and Experimental Hypertension, Part A. 5 (7–8): 1263–75. doi:10.3109/10641968309048856. PMID 6315268.
  20. ^ "Angiotensin converting enzyme (ace) inhibitors" (PDF). British Hypertension Society. Archived from the original (PDF) on 2017-11-18.
  21. ^ Klabunde RE. "ACE-inhibitors". Cardiovascular Pharmacology Concepts. cvpharmacology.com. Retrieved 2009-03-26.
  22. ^ Brooks L (2004). "The Importance of Treating the Blood Pressure: ACE Inhibitors May Slow Alzheimer's Disease". Medscape. Medscape Cardiology.
  23. ^ Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, Phillips L, Qiao L, Budson AE, Stern R, Kowall N (2013-01-01). "Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele". Journal of Alzheimer's Disease. 37 (2): 421–8. doi:10.3233/JAD-130716. PMC 3972060. PMID 23948883.
  24. ^ "ACE Enzyme May Enhance Immune Responses And Prevent Alzheimer's". Science 2.0. 27 August 2014. Retrieved 2016-03-01.
  25. ^ Joris R. Delanghe, Marijn M. Speeckaert, Marc L. De Buyzere (2020). "The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections". Clinica Chimica Acta; International Journal of Clinical Chemistry. 505: 192–193. doi:10.1016/j.cca.2020.03.031. PMC 7102561. PMID 32220422.CS1 maint: multiple names: authors list (link)
  26. ^ Jump up to: a b c Cintra, Mariangela Torreglosa Ruiz; Balarin, Marly Aparecida Spadotto; Tanaka, Sarah Cristina Sato Vaz; Silva, Vanessa Iorrana Mota da; Marqui, Alessandra Bernadete Trovó de; Resende, Elisabete Aparecida Mantovani Rodrigues de; Lima, Marco Fábio Prata; Gomes, Mariana Kefálas Oliveira (November 2018). "Polycystic ovarian syndrome: rs1799752 polymorphism of ACE gene". Revista da Associação Médica Brasileira. 64 (11): 1017–1022. doi:10.1590/1806-9282.64.11.1017. PMID 30570054.
  27. ^ Flück, Martin; Kramer, Manuel; Fitze, Daniel P.; Kasper, Stephanie; Franchi, Martino V.; Valdivieso, Paola (8 May 2019). "Cellular Aspects of Muscle Specialization Demonstrate Genotype – Phenotype Interaction Effects in Athletes". Frontiers in Physiology. 10: 526. doi:10.3389/fphys.2019.00526. PMC 6518954. PMID 31139091.
  28. ^ Wang P, Fedoruk MN, Rupert JL (2008). "Keeping pace with ACE: are ACE inhibitors and angiotensin II type 1 receptor antagonists potential doping agents?". Sports Medicine. 38 (12): 1065–79. doi:10.2165/00007256-200838120-00008. PMID 19026021. S2CID 7614657.
  29. ^ Jump up to: a b Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H, Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P, McEwan JR, McKenna WJ, Humphries S (Aug 1997). "Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training". Circulation. 96 (3): 741–7. doi:10.1161/01.CIR.96.3.741. PMID 9264477.
  30. ^ Sanders J, Montgomery H, Woods D (2001). "Kardiale Anpassung an Körperliches Training" [The cardiac response to physical training] (PDF). Deutsche Zeitschrift für Sportmednizin (in German). Jahrgang 52 (3): 86–92.
  31. ^ Costa AM, Silva AJ, Garrido ND, Louro H, de Oliveira RJ, Breitenfeld L (Aug 2009). "Association between ACE D allele and elite short distance swimming". European Journal of Applied Physiology. 106 (6): 785–90. doi:10.1007/s00421-009-1080-z. hdl:10400.15/3565. PMID 19458960. S2CID 21167767.

Further reading[]

External links[]

Retrieved from ""